MacroGenics, Inc. (NASDAQ:MGNX) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, October 31st. Analysts expect the company to announce earnings of ($0.89) per share for the quarter.
MacroGenics (NASDAQ:MGNX) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.09). The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $15.82 million. MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The business’s revenue for the quarter was down 97.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.12 earnings per share. On average, analysts expect MacroGenics to post $-4.24 EPS for the current fiscal year and $-4.03 EPS for the next fiscal year.
MacroGenics, Inc. (MGNX) opened at 19.45 on Monday. MacroGenics, Inc. has a one year low of $14.36 and a one year high of $31.85. The company’s market capitalization is $715.72 million. The firm has a 50-day moving average of $17.70 and a 200-day moving average of $18.15.
In other news, SVP Jon Marc Wigginton sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, October 25th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. Following the sale, the senior vice president now owns 40,000 shares of the company’s stock, valued at approximately $800,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.30% of the stock is currently owned by company insiders.
A number of research firms have issued reports on MGNX. Stifel Nicolaus reaffirmed a “buy” rating and issued a $34.00 price target on shares of MacroGenics in a research report on Tuesday, September 12th. Cowen and Company reaffirmed a “buy” rating on shares of MacroGenics in a research report on Friday, August 4th. ValuEngine lowered MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd. BidaskClub lowered MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. Finally, Morgan Stanley reduced their price target on MacroGenics from $22.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Monday, August 7th. Three analysts have rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $30.30.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
What are top analysts saying about MacroGenics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MacroGenics Inc. and related companies.